542 related articles for article (PubMed ID: 11259329)
1. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
2. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.
Yamano K; Yamamoto K; Kotaki H; Sawada Y; Iga T
Drug Metab Dispos; 1999 Mar; 27(3):395-402. PubMed ID: 10064572
[TBL] [Abstract][Full Text] [Related]
3. Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver.
Yamano K; Yamamoto K; Kotaki H; Takedomi S; Matsuo H; Sawada Y; Iga T
J Pharmacol Exp Ther; 2000 Mar; 292(3):1118-26. PubMed ID: 10688631
[TBL] [Abstract][Full Text] [Related]
4. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
Ito K; Ogihara K; Kanamitsu S; Itoh T
Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
[TBL] [Abstract][Full Text] [Related]
5. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
6. Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats.
Takedomi S; Matsuo H; Yamano K; Yamamoto K; Iga T; Sawada Y
Drug Metab Dispos; 1998 Apr; 26(4):318-23. PubMed ID: 9531518
[TBL] [Abstract][Full Text] [Related]
7. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
9. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
[TBL] [Abstract][Full Text] [Related]
10. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
11. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
12. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.
Witherow LE; Houston JB
J Pharmacol Exp Ther; 1999 Jul; 290(1):58-65. PubMed ID: 10381760
[TBL] [Abstract][Full Text] [Related]
13. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
15. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.
Zhang X; Galinsky RE; Kimura RE; Quinney SK; Jones DR; Hall SD
Drug Metab Dispos; 2010 Jan; 38(1):61-72. PubMed ID: 19797607
[TBL] [Abstract][Full Text] [Related]
17. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
Cheng CL; Smith DE; Carver PL; Cox SR; Watkins PB; Blake DS; Kauffman CA; Meyer KM; Amidon GL; Stetson PL
Clin Pharmacol Ther; 1997 May; 61(5):531-43. PubMed ID: 9164415
[TBL] [Abstract][Full Text] [Related]
18. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs.
Mills BM; Zaya MJ; Walters RR; Feenstra KL; White JA; Gagne J; Locuson CW
Drug Metab Dispos; 2010 Mar; 38(3):396-404. PubMed ID: 20007294
[TBL] [Abstract][Full Text] [Related]
19. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.
Lai L; Hao H; Wang Q; Zheng C; Zhou F; Liu Y; Wang Y; Yu G; Kang A; Peng Y; Wang G; Chen X
Drug Metab Dispos; 2009 Dec; 37(12):2399-407. PubMed ID: 19741040
[TBL] [Abstract][Full Text] [Related]
20. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
